Markers of disease severity in chronic obstructive pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 19, Issue 3, 2006, Pages 189-199

  Franciosi, Luigi G ^a   Page, Clive P ^b   Celli, Bartolome R ^c   Cazzola, Mario ^b,d   Walker, Michael J ^e   Danhof, Meindert ^a   Rabe, Klaus F ^f   Pasqua, Oscar E Della ^a,g  

^a LEIDEN UNIVERSITY   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c TUFTS UNIVERSITY   (United States)

^d CARDARELLI HOSPITAL   (Italy)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Biological marker; COPD; Disease progression; Mathematical model

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ARTERIAL OXYGEN TENSION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; MATHEMATICAL MODEL; META ANALYSIS; METHODOLOGY; NEUTROPHIL; PRIORITY JOURNAL; QUESTIONNAIRE; SPIROMETRY; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MACROPHAGES; NEUTROPHILS; PUBMED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SPUTUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644985112     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2005.05.001     Document Type: Article

References (61)

1. American Thoracic Society/European Respiratory Society. Definition, Diagnosis and Staging of COPD. American Thoracic Society Website 2004 May 24 [cited 2004 May 24]; Available from: URL: http://www.thoracic.org/COPD/1/ definitions.asp.
2. T.L. Croxton, G.G. Weinmann, R.M. Senior, R.A. Wise, J.D. Crapo, and A.S. Buist Clinical research in chronic obstructive pulmonary disease: needs and opportunities Am J Respir Crit Care Med 167 8 2003 1142 1149
3. P.M. Calverley, and P. Walker Chronic obstructive pulmonary disease Lancet 362 9389 2003 1053 1061
4. N.M. Siafakas, P. Vermeire, N.B. Pride, P. Paoletti, J. Gibson, and P. Howard Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European respiratory society task force Eur Respir J 8 8 1995 1398 1420
5. The COPD Guidelines Group of the Standards of Care Committee of the BTS BTS guidelines for the management of chronic obstructive pulmonary disease Thorax 52 5 1997 S1 S28
6. American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 152 5 Pt 2 1995 S77 S121
7. C. Fletcher, and R. Peto The natural history of chronic airflow obstruction Br Med J 1 6077 1977 1645 1648
8. N.R. Anthonisen, J.E. Connett, and R.P. Murray Smoking and lung function of Lung Health Study participants after 11 years Am J Respir Crit Care Med 166 5 2002 675 679
9. P.S. Burge, P.M. Calverley, P.W. Jones, S. Spencer, J.A. Anderson, and T.K. Maslen Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial BMJ 320 7245 2000 1297 1303
10. R.A. Pauwels, C.G. Lofdahl, L.A. Laitinen, J.P. Schouten, D.S. Postma, and N.B. Pride Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European respiratory society study on chronic obstructive pulmonary disease N Engl J Med 340 25 1999 1948 1953
11. J. Vestbo, T. Sorensen, P. Lange, A. Brix, P. Torre, and K. Viskum Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial Lancet 353 9167 1999 1819 1823
12. Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease N Engl J Med 343 26 2000 1902 1909
13. D.C. Weir, G.A. Bale, P. Bright, and B.P. Sherwood A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease Clin Exp Allergy 29 2 1999 125 128
14. P.J. Barnes Mechanisms in COPD: differences from asthma Chest 117 2 2000 10S 14S
15. R. Kessler, M. Faller, G. Fourgaut, B. Mennecier, and E. Weitzenblum Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 159 1 1999 158 164
16. S.T. Weiss, D.L. DeMeo, and D.S. Postma COPD: problems in diagnosis and measurement Eur Respir J Suppl 41 2003 4s 12s
17. R.O. Crapo, R.L. Jensen, and F.E. Hargreave Airway inflammation in COPD: physiological outcome measures and induced sputum Eur Respir J Suppl 41 2003 19s 28s
18. E.F. Wouters, E.C. Creutzberg, and A.M. Schols Systemic effects in COPD Chest 121 5 2002 127S 130S
19. A.G. Agusti, A. Noguera, J. Sauleda, E. Sala, J. Pons, and X. Busquets Systemic effects of chronic obstructive pulmonary disease Eur Respir J 21 2 2003 347 360
20. D.P. Tashkin, M.D. Altose, J.E. Connett, R.E. Kanner, W.W. Lee, and R.A. Wise Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study research group Am J Respir Crit Care Med 153 6 Pt 1 1996 1802 1811
21. P.D. Scanlon, J.E. Connett, L.A. Waller, M.D. Altose, W.C. Bailey, and A.S. Buist Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study Am J Respir Crit Care Med 161 2 Pt 1 2000 381 390
22. S.R. Rutgers, W. Timens, H.F. Kauffman, and D.S. Postma Markers of active airway inflammation and remodelling in chronic obstructive pulmonary disease Clin Exp Allergy 31 2 2001 193 205
23. N. Yasuda, K. Gotoh, S. Minatoguchi, K. Asano, K. Nishigaki, and M. Nomura An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD Respir Med 92 8 1998 993 999
24. P.J. Barnes Chronic obstructive pulmonary disease N Engl J Med 343 4 2000 269 280
25. R.E. Walter, A. Beiser, R.J. Givelber, G.T. O'Connor, and D.J. Gottlieb Association between glycemic state and lung function: the Framingham heart study Am J Respir Crit Care Med 167 6 2003 911 916
26. M. Dahl, A. Tybjaerg-Hansen, J. Vestbo, P. Lange, and B.G. Nordestgaard Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 6 2001 1008 1011
27. D. Dev, E. Wallace, R. Sankaran, J. Cunniffe, J.R. Govan, and C.G. Wathen Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease Respir Med 92 4 1998 664 667
28. N. Soler, S. Ewig, A. Torres, X. Filella, J. Gonzalez, and A. Zaubet Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease Eur Respir J 14 5 1999 1015 1022
29. J. Zhu, S. Majumdar, Y. Qiu, T. Ansari, A. Oliva, and J.C. Kips Interleukin-4 and interleukin-5 gene expression and inflammation in the mucus-secreting glands and subepithelial tissue of smokers with chronic bronchitis. Lack of relationship with CD8(+) cells Am J Respir Crit Care Med 164 12 2001 2220 2228
30. A. Bhowmik, T.A. Seemungal, R.J. Sapsford, and J.A. Wedzicha Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations Thorax 55 2 2000 114 120
31. C. Landbo, E. Prescott, P. Lange, J. Vestbo, and T.P. Almdal Prognostic value of nutritional status in chronic obstructive pulmonary disease Am J Respir Crit Care Med 160 6 1999 1856 1861
32. R.A. Stockley Neutrophils and the pathogenesis of COPD Chest 121 5 2002 151S 155S
33. K.M. Beeh, J. Beier, O. Kornmann, A. Mander, and R. Buhl Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD Chest 123 3 2003 778 783
34. V.M. Keatings, P.D. Collins, D.M. Scott, and P.J. Barnes Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma Am J Respir Crit Care Med 153 2 1996 530 534
35. S. Sakao, K. Tatsumi, H. Igari, R. Watanabe, Y. Shino, and H. Shirasawa Association of tumor necrosis factor-alpha gene promoter polymorphism with low attenuation areas on high-resolution CT in patients with COPD Chest 122 2 2002 416 420
36. American Thoracic Society Lung function testing: selection of reference values and interpretative strategies Am Rev Respir Dis 144 5 1991 1202 1218
37. B. Burrows, M.D. Lebowitz, A.E. Camilli, and R.J. Knudson Longitudinal changes in forced expiratory volume in one second in adults. Methodologic considerations and findings in healthy nonsmokers Am Rev Respir Dis 133 6 1986 974 980
38. R.J. Knudson, M.D. Lebowitz, C.J. Holberg, and B. Burrows Changes in the normal maximal expiratory flow-volume curve with growth and aging Am Rev Respir Dis 127 6 1983 725 734
39. R.O. Crapo, A.H. Morris, and R.M. Gardner Reference spirometric values using techniques and equipment that meet ATS recommendations Am Rev Respir Dis 123 6 1981 659 664
40. P. Paoletti, G. Pistelli, P. Fazzi, G. Viegi, P.F. Di, and G. Giuliano Reference values for vital capacity and flow-volume curves from a general population study Bull Eur Physiopathol Respir 22 5 1986 451 459
41. M.D. Lebowitz, J. Quackenboss, A.E. Camilli, D. Bronnimann, C.J. Holberg, and B. Boyer The epidemiological importance of intraindividual changes in objective pulmonary responses Eur J Epidemiol 3 4 1987 390 398
42. G.M. Cochrane, F. Prieto, and T.J. Clark Intrasubject variability of maximal expiratory flow volume curve Thorax 32 2 1977 171 176
43. M.R. Miller, and A.C. Pincock Predicted values: how should we use them? Thorax 43 4 1988 265 267
44. A.J. Miller Pulmonary function tests in clinical and occupational lung disease 1986 Grune and Stratton Orlando
45. P.D. Oldham Percent of predicted as the limit of normal in pulmonary function testing: a statistically valid approach Thorax 34 4 1979 569 570
46. B.J. Sobol Assessment of ventilatory abnormality in the asymptomatic subject: an exercise in futility Thorax 21 5 1966 445 449
47. B.R. Celli, and W. MacNee Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur Respir J 23 6 2004 932 946
48. L.M. Fabbri, and S.S. Hurd Global strategy for the diagnosis, management and prevention of COPD: update Eur Respir J 22 1 2003 1 2
49. R.A. Pauwels, A.S. Buist, P.M. Calverley, C.R. Jenkins, and S.S. Hurd Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global initiative for chronic obstructive lung disease (GOLD) workshop summary Am J Respir Crit Care Med 163 5 2001 1256 1276
50. L.V. Hedges, and J.L. Vevea Fixed- and random-effects models in meta-analysis Psychol Methods 3 4 1998 486 504
51. V.G. De Gruttola, P. Clax, D.L. DeMets, G.J. Downing, S.S. Ellenberg, and L. Friedman Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a national institutes of health workshop Control Clin Trials 22 5 2001 485 502
52. R. Frank, and R. Hargreaves Clinical biomarkers in drug discovery and development Nat Rev Drug Discov 2 7 2003 566 580
53. M. Saetta, G. Turato, P. Maestrelli, C.E. Mapp, and L.M. Fabbri Cellular and structural bases of chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 6 2001 1304 1309
54. D.L. Sherrill, M.D. Lebowitz, and B. Burrows Epidemiology of chronic obstructive pulmonary disease Clin Chest Med 11 3 1990 375 387
55. C. Schulz, K. Kratzel, K. Wolf, S. Schroll, M. Kohler, and M. Pfeifer Activation of bronchial epithelial cells in smokers without airway obstruction and patients with COPD Chest 125 5 2004 1706 1713
56. T. Eaton, S. Withy, J.E. Garrett, J. Mercer, R.M. Whitlock, and H.H. Rea Spirometry in primary care practice: the importance of quality assurance and the impact of spirometry workshops Chest 116 2 1999 416 423
57. B.R. Celli, C.G. Cote, J.M. Marin, C. Casanova, O.M. Montes de, and R.A. Mendez The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease N Engl J Med 350 10 2004 1005 1012
58. W.A. Colburn Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development J Clin Pharmacol 40 12 Pt 2 2000 1419 1427
59. L. Aarons, M.O. Karlsson, F. Mentre, F. Rombout, J.L. Steimer, and A. van Peer Role of modelling and simulation in Phase I drug development Eur J Pharm Sci 13 2 2001 115 122
60. Danhof M. Markers of Pharmacological and Toxicological Action. Haemostas Foundation Leiden Workshop 2001 April 19 [cited 2004 May 24]; Available from: URL: http://www.haemostas.nl/files/abstract23danhof.doc.
61. S. Borg, A. Ericsson, J. Wedzicha, A. Gulsvik, B. Lundback, and G.C. Donaldson A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease Value Health 7 2 2004 153 167